AI assistant
COLLEGIUM PHARMACEUTICAL, INC — Director's Dealing 2021
Mar 4, 2021
32163_dirs_2021-03-03_fd3ed0be-59dd-4e9e-8bfe-6bd592c21351.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK: 0001267565
Period of Report: 2021-03-01
Reporting Person: Ciaffoni Joseph (Director, President and CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2021-03-01 | Common Stock | M | 48616 | $8.22 | Acquired | 343075 | Direct |
| 2021-03-01 | Common Stock | S | 54959 | $22.56 | Disposed | 288116 | Direct |
| 2021-03-01 | Common Stock | S | 9809 | $23.3 | Disposed | 278307 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2021-03-01 | Stock Option (Right to Purchase) | $8.22 | M | 48616 | Disposed | 2027-05-31 | Common Stock (48616) | Direct |
Footnotes
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 11, 2020.
F2: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.01 to $22.98, inclusive. The reporting person undertakes to provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) and (3).
F3: The price reported in column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $23.00 to $23.54, inclusive.
F4: 48,616 shares under the option are exercisable. The option, initially representing a right to purchase a total of 259,283 shares, vests and becomes exercisable over a four-year period commencing on May 31, 2017. Twenty-five percent (25%) of the option vested and became exercisable on May 31, 2018 and the balance vests in equal quarterly installments (rounded up to the nearest whole share of common stock) at the end of each quarterly period over the remaining three years of the four-year period, subject to the reporting person's continued service with the Issuer.